Dan Kaufman, MD
Hematology & Oncology · San Diego, CANPI 1801985726
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,160 of the $17,109 with a category attached, or 76.9%. Merck accounts for 61.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $10,575 and has fallen 96.8% since, to $337 in 2025.
Across 19 payments — averaging $900.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$11K
- Gilead$4K
- Kyowa Kirin, Inc.$2K
- Cook Medical LLC$174
- Karyopharm Therapeutics Inc.$91
- Janssen Research & Development, LLC$72
- plus $50 from 2 others
Across 1 payment — averaging $193,941 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$194K
What the payments were for
- Consulting fees$13,16077%
- Speaking & faculty fees$2,00012%
- Travel & lodging$1,2677%
- Food & beverage$6824%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 12 | $10,562 |
| Gilead | 1 | $4,160 |
| Kyowa Kirin, Inc. | 1 | $2,000 |
| Cook Medical LLC | 1 | $174 |
| Karyopharm Therapeutics Inc. | 1 | $91 |
| Janssen Research & Development, LLC | 1 | $72 |
| Iovance Biotherapeutics, Inc. | 1 | $38 |
| Vapotherm Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zenith Alpha$174
How this compares
$17,109 in reported general payments places this provider in the 75th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in San Diego
- Wendy LevinSan Diego$760K
- Rana McKaySan Diego$530K
- Ezra CohenSan Diego$495K
- Annette von DrygalskiSan Diego$406K
- Lyudmila BazhenovaSan Diego$328K
- Sandip PatelSan Diego$295K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.